TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20678689

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl 0.05 mg/0.1 mL
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (preserved normal saline) 0.1 mL
Number of subjects: 36
Study: 20805137

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT) in addition to conventional medical therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional medical therapy alone
Number of subjects: 100
Study: 16193890

Group type: EXPERIMENTAL
Intervention: High dose oral methylprednisolone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11890187

Group type: EXPERIMENTAL
Intervention: 30 mg/day mianserin (n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 18
Study: 9716143

Group type: EXPERIMENTAL
Intervention: CTEPH patients
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: PPH patients
Number of subjects: 140

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 140
Study: 7913907

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 70
Study: 3054651

Group type: EXPERIMENTAL
Intervention: Single-dose piperacillin
Number of subjects: 209

Group type: COMPARATOR
Intervention: Triple-dose cefoxitin
Number of subjects: 209
Study: 29795314

Group type: EXPERIMENTAL
Intervention: Rescue antenatal steroids (ideal treatment)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Rescue antenatal steroids (remote treatment)
Number of subjects: 56
Study: 27059830

Group type: EXPERIMENTAL
Intervention: Vibratory stimulus applied for 2 minutes before and after meals for 5 days.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonvibratory controls (no vibratory stimulus applied).
Number of subjects: 16
Study: 25582493

Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m² and pemetrexed 500 mg/m², every 3 weeks for 6 cycles followed by maintenance pemetrexed
Number of subjects: 118

Group type: COMPARATOR
Intervention: Carboplatin AUC 6, paclitaxel 200 mg/m², and bevacizumab 15 mg/kg, every 3 weeks for 6 cycles followed by maintenance bevacizumab
Number of subjects: 118
Study: 24300198

Group type: EXPERIMENTAL
Intervention: Standardized out-of-hospital management, regular health education, and follow-ups via telephone and outpatient visits.
Number of subjects: 734

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 734
Study: 19915784

Group type: EXPERIMENTAL
Intervention: Client-keyworker relationship
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Client-vocational worker relationship (rated by client)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Vocational worker-rated relationship
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Client-keyworker and client-vocational worker relationships
Number of subjects: 312
Study: 18959451

Group type: EXPERIMENTAL
Intervention: Pacifier-Activated Lullaby (PAL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pacifier-Only
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-Contact
Number of subjects: 60
Study: 16039496

Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 82

Group type: COMPARATOR
Intervention: Topical anesthesia
Number of subjects: 82
Study: 12525720

Group type: EXPERIMENTAL
Intervention: GDNF 25 microg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GDNF 75 microg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GDNF 150 microg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GDNF 300 microg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GDNF 500 microg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GDNF 4000 microg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 10847254

Group type: EXPERIMENTAL
Intervention: Warfarin therapy with INR > 6.0
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: INR > 6.0
Number of subjects: 114

Group type: COMPARATOR
Intervention: INR in target range (2.0 to 3.0)
Number of subjects: 114
Study: 8664133

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) at 160 mg day‐1
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) at 320 mg day‐1
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) at 320 mg day‐1 (further therapy)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) at 480 mg day‐1 (further therapy)
Number of subjects: 122
Study: 1514886

Group type: EXPERIMENTAL
Intervention: Clean intermittent catheterization
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sterile intermittent catheterization
Number of subjects: 46
Study: 6740497

Group type: EXPERIMENTAL
Intervention: Anti-estrogen therapy (tamoxifen, Nolvadex) added to chemotherapy (cyclophosphamide, methotrexate, and fluorouracil - CMF)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Nonspecific immunotherapy with bacillus Calmette-Guerin
Number of subjects: 312
Study: 29969366

Group type: EXPERIMENTAL
Intervention: Children with ALL treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 29604548

Group type: EXPERIMENTAL
Intervention: Non-ablative Er:YAG laser therapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 114
Study: 26759000

Group type: EXPERIMENTAL
Intervention: Body weight-based prednisolone (BW)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Body surface area-based prednisolone (BSA)
Number of subjects: 100
Study: 25304789

Group type: EXPERIMENTAL
Intervention: Synbiotic powder containing Lactobacillus reuteri 10(8) CFU and 4.3 g of soluble fiber
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22505658

Group type: EXPERIMENTAL
Intervention: Surgery + Radiotherapy (S + RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 0
Study: 19828469

Group type: EXPERIMENTAL
Intervention: Structured feedback provided by an experienced supervisor
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-feedback group (control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 17852417

Group type: EXPERIMENTAL
Intervention: Intravenous pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) during E2-only withdrawal
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intravenous pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) during withdrawal from E2 + P
Number of subjects: 26
Study: 16199359

Group type: EXPERIMENTAL
Intervention: Student-led tutorials (SLT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Faculty-led tutorials (FLT)
Number of subjects: 91
Study: 12084370

Group type: EXPERIMENTAL
Intervention: Group Intervention (GI)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Short Individual Intervention (SII)
Number of subjects: 106
Study: 9524981

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 86
Study: 7714935

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy (nalidixic acid)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ineffective antimicrobial therapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Clinical features and laboratory tests
Number of subjects: 33
Study: 2665385

Group type: EXPERIMENTAL
Intervention: Mictonorm (45 mg/d)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Spasuret (300 mg/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 20917

Group type: EXPERIMENTAL
Intervention: Clobazam (10 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clobazam (20 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Triflubazam (20 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Triflubazam (40 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 6
Study: 31982072

Group type: EXPERIMENTAL
Intervention: Pembrolizumab with chemotherapy
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Pembrolizumab alone
Number of subjects: 307

Group type: COMPARATOR
Intervention: Cetuximab with chemotherapy
Number of subjects: 307
Study: 31482784

Group type: EXPERIMENTAL
Intervention: Care-seeking behavior
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Younger age of child (infants compared with children)
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Caretaker with primary education compared with none
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Vaccine awareness
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Breastfeeding awareness
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Presence of fever
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Presence of tachypnea
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Presence of chest indrawing
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Presence of persistent vomiting
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Presence of recurrent illness
Number of subjects: 1152
Study: 28418269

Group type: EXPERIMENTAL
Intervention: Hollow centralizer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Solid centralizer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 25995301

Group type: EXPERIMENTAL
Intervention: Adjuvant anthracyclines
Number of subjects: 816

Group type: COMPARATOR
Intervention: No chemotherapy (control group)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Continuous It-TIL
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Continuous Str-TIL
Number of subjects: 816
Study: 23375815

Group type: EXPERIMENTAL
Intervention: Dual-source CT with a pitch of 3.0 and bolus triggering at 140 HU with a delay of 10s (group 2)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: High-pitch CT angiography (group 2, 3, and 4)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional single-source CT with a pitch of 1.2 (group 1)
Number of subjects: 160
Study: 21334221

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) training using the wave form of 20 Hz exponential pulse from the 2nd post‐operative day to 4 weeks after the surgery.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual rehabilitation program (Control group).
Number of subjects: 20
Study: 19135906

Group type: EXPERIMENTAL
Intervention: Home-visitation services (n=236)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control group (n=265)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Home-visitation services for mothers exposed at gestational age of <=24 weeks
Number of subjects: 501
Study: 17570424

Group type: EXPERIMENTAL
Intervention: Tolterodine ER (4 mg QD)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study: 15155304

Group type: EXPERIMENTAL
Intervention: Percutaneous electrical nerve stimulation (PENS) for 8 weeks (Group A)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Percutaneous electrical nerve stimulation (PENS) for 4 weeks followed by transcutaneous electrical nerve stimulation (TENS) for 4 weeks (Group B)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) for 8 weeks (Group C)
Number of subjects: 53
Study: 11448394

Group type: EXPERIMENTAL
Intervention: Adhesive paper tape (PT group)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Interrupted suture (IS group)
Number of subjects: 300
Study: 9079242

Group type: EXPERIMENTAL
Intervention: Test preparation (250 mg flutamide)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference preparation (250 mg flutamide)
Number of subjects: 20
Study: 8485068

Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg bid for 4 weeks
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg bid for 4 weeks (if needed)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Isradipine (1.25 mg bid)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 101
Study: 2875003

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS) 30 mg/kg intravenous (maximum dose 3 g)
Number of subjects: 1118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS)
Number of subjects: 1118
Study: 31660983

Group type: EXPERIMENTAL
Intervention: CS-DANTE-SPACE
Number of subjects: 38

Group type: COMPARATOR
Intervention: DANTE-SPACE
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: CS-DANTE-SPACE and DANTE-SPACE
Number of subjects: 38
Study: 28067979

Group type: EXPERIMENTAL
Intervention: D.T. Light-Post-removal kit
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Start-X stainless-steel ultrasonic tips
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (fiber posts left without removal)
Number of subjects: 45
Study: 27797095

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided superficial/combined cervical plexus block
Number of subjects: 98

Group type: COMPARATOR
Intervention: Infiltration anaesthesia
Number of subjects: 98
Study: 24658627

Group type: EXPERIMENTAL
Intervention: Lenvatinib 32 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 52
Study: 22789455

Group type: EXPERIMENTAL
Intervention: Tailored Intervention
Number of subjects: 268

Group type: COMPARATOR
Intervention: Wellness Contact Control
Number of subjects: 268
Study: 20075789

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE) with tri-iodothyronine +/- methylprednisolone therapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Initial echocardiography
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Repeat echocardiography
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PAC-guided management
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Thyroid status and hormonal therapy
Number of subjects: 66
Study: 18341818

Group type: EXPERIMENTAL
Intervention: PCI combined percutaneous thrombectomy group
Number of subjects: 56

Group type: COMPARATOR
Intervention: PCI group
Number of subjects: 56
Study: 15725970

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 12
Study: 14685056

Group type: EXPERIMENTAL
Intervention: TMC125 monotherapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Five-drug regimen (zidovudine, lamivudine, abacavir, indinavir, nevirapine)
Number of subjects: 12
Study: 10590488

Group type: EXPERIMENTAL
Intervention: Electrophysiologically guided antiarrhythmic drug therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 0
Study: 8851370

Group type: EXPERIMENTAL
Intervention: TTS fentanyl (Duragesic, TTS‐F)
Number of subjects: 39
Study: 1308377

Group type: EXPERIMENTAL
Intervention: EMLA occluded with Orahesive Oral Bandages
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6589647

Group type: EXPERIMENTAL
Intervention: Triamterene 200 mg/d
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Amiloride 15 mg/d
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acetazolamide 750 mg/d
Number of subjects: 18
Study: 3539032

Group type: EXPERIMENTAL
Intervention: Combination of inhaled and oral salbutamol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Inhaled dry powder of salbutamol
Number of subjects: 56
Study: 30953835

Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27816366

Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ondansetron (8 mg)
Number of subjects: 90
Study: 26571889

Group type: EXPERIMENTAL
Intervention: Combined therapy (massage therapy + magnetic sticking therapy at auricular points)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Simple massage therapy
Number of subjects: 72
Study: 23127919

Group type: EXPERIMENTAL
Intervention: Inactivated virus vaccine (one dose)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Inactivated virus vaccine (two doses)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: MLV vaccine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Inactivated virus vaccine (one or two doses)
Number of subjects: 59
Study: 21558878

Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe (40 mg/d + 10 mg/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Simvastatin + Placebo (40 mg/d + placebo)
Number of subjects: 46
Study: 18295624

Group type: EXPERIMENTAL
Intervention: Electric stimulation (ES) during cycling training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cycling training without electric stimulation (control)
Number of subjects: 12
Study: 16579803

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (5000 or 10,000 iu daily)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 12548041

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine stress 99mTc tetrofosmin (DSTF) quantitative gated SPECT
Number of subjects: 24
Study: 11508317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Grape Seed Extract (GSE) 100 mg bid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chromium Polynicotinate (Cr) 200 microg bid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of Cr and GSE (200 microg Cr and 100 mg GSE bid)
Number of subjects: 40
Study: 9124549

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) infusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Vehicle (5% dextrose in water)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Lisinopril (5 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: AVP infusion after lisinopril
Number of subjects: 7
Study: 1326902

Group type: EXPERIMENTAL
Intervention: gamma-hydroxybutyric acid (50 mg/kg/day, divided into three daily doses)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: gamma-hydroxybutyric acid
Number of subjects: 82
Study: 3921173

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31975413

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 mcg/kg bwt
Number of subjects: 99

Group type: COMPARATOR
Intervention: Romifidine 20 mcg/kg bwt
Number of subjects: 99
Study: 30879447

Group type: EXPERIMENTAL
Intervention: Pelvic height planning
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional templating
Number of subjects: 200
Study: 27803216

Group type: EXPERIMENTAL
Intervention: Dual mobility acetabular component
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard polyethylene component
Number of subjects: 20
Study: 24831977

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg every 3 weeks for up to four doses, with maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death.
Number of subjects: 799

Group type: COMPARATOR
Intervention: Placebo every 3 weeks for up to four doses, with maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death.
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 799

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 799
Study: 22511399

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 20464778

Group type: EXPERIMENTAL
Intervention: Heliox-powered nebulized albuterol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Air/oxygen-powered nebulized albuterol (placebo)
Number of subjects: 42
Study: 18824462

Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg simvastatin and 10 mg ezetimibe combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-obese healthy controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obese men with metabolic syndrome (baseline)
Number of subjects: 0
Study: 16000605

Group type: EXPERIMENTAL
Intervention: Cisplatin-based adjuvant chemotherapy
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (platinum-based)
Number of subjects: 1394
Study: 12794583

Group type: EXPERIMENTAL
Intervention: Topical nifedipine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Topical glyceryl trinitrate
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 52
Study: 9927017

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (5.03 g CHO x kg BM(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate diet (3.89 g CHO x kg BM(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maximal exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lactic acid-threshold (LAT) exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lactic acid-threshold -20 (LAT-20) exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (nonexercise session)
Number of subjects: 12
Study: 7778023

Group type: EXPERIMENTAL
Intervention: M-PLA2
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: PMN-E
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: t-PA
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: u-PA
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: ET-1
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Combination of M-PLA2, PMN-E, and t-PA
Number of subjects: 184
Study: 2361776

Group type: EXPERIMENTAL
Intervention: Negative ion condition
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 73
Study: 155891

Group type: EXPERIMENTAL
Intervention: 80 microgram ipratropium
Number of subjects: 21

Group type: COMPARATOR
Intervention: 200 microgram salbutamol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of ipratropium and salbutamol
Number of subjects: 21